Erratum: Epigallocatechin‑3‑gallate inhibits nicotine‑induced migration and invasion by the suppression of angiogenesis and epithelial‑mesenchymal transition in non‑small cell lung cancer cells (Oncology Reports (2015) 33 (2972‑2980) DOI: 10.3892/or.2015.3889);Epigallocatechin-3-gallate inhibits nicotine-induced migration and invasion by the suppression of angiogenesis and epithelial-mesenchymal transition in non-small cell lung cancer cells

Oncology Reports

Volumn 33, Issue 6, 2015, Pages 2972-2980

  Shi, Jingli ^a   Liu, Fei ^a   Zhang, Wenzhang ^a   Liu, Xin ^a   Lin, Bihua ^a   Tang, Xudong ^a  

^a GUANGDONG MEDICAL UNIVERSITY   (China)

Author keywords

Angiogenesis; Epigallocatechin 3 gallate; Epithelial mesenchymal transition; Invasion; Migration; Nicotine; Non small cell lung cancer

Indexed keywords

BETA CATENIN; CYCLOOXYGENASE 2; EPIGALLOCATECHIN GALLATE; HEMOGLOBIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; NICOTINE; PROTEIN KINASE B; PROTEIN P53; SMALL INTERFERING RNA; VASCULOTROPIN; VIMENTIN; CATECHIN; TEA; TUMOR PROTEIN;

A549 CELL LINE; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SMOKING; TUMOR INVASION; TUMOR XENOGRAFT; UPREGULATION; ADVERSE EFFECTS; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; GENETICS; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; TEA; TUMOR CELL LINE;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CATECHIN; CELL LINE, TUMOR; CELL MOVEMENT; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; MICE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOVASCULARIZATION, PATHOLOGIC; NICOTINE; SMOKING; TEA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84928894776     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/OR.2023.8614     Document Type: Erratum

References (48)

1. Pesch B, Kendzia B, Gustavsson P, Jöckel KH, Johnen G, Pohlabeln H, Olsson A, Ahrens W, Gross IM, Brüske I, et al: Cigarette smoking and lung cancer - relative risk estimates for the major histological types from a pooled analysis of case-control studies. Int J Cancer 131: 1210-1219, 2012.
2. Schaal C and Chellappan SP: Nicotine-mediated cell proliferation and tumor progression in smoking-related cancers. Mol Cancer Res 12: 14-23, 2014.
3. Nair S, Bora-Singhal N, Perumal D and Chellappan S: Nicotinemediated invasion and migration of non-small cell lung carcinoma cells by modulating STMN3 and GSPT1 genes in an ID1-dependent manner. Mol Cancer 13: 173, 2014.
4. Dasgupta P, Rizwani W, Pillai S, Kinkade R, Kovacs M, Rastogi S, Banerjee S, Carless M, Kim E, Coppola D, et al: Nicotine induces cell proliferation, invasion and epithelialmesenchymal transition in a variety of human cancer cell lines. Int J Cancer 124: 36-45, 2009.
5. Wu SQ, Lv YE, Lin BH, Luo LM, Lv SL, Bi AH and Jia YS: Silencing of periostin inhibits nicotine-mediated tumor cell growth and epithelial-mesenchymal transition in lung cancer cells. Mol Med Rep 7: 875-880, 2013.
6. Jackson AL, Zhou B and Kim WY: HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. Expert Opin Ther Targets 14: 1047-1057, 2010.
7. Creighton CJ, Gibbons DL and Kurie JM: The role of epithelialmesenchymal transition programming in invasion and metastasis: A clinical perspective. Cancer Manag Res 5: 187-195, 2013.
8. Zhang Q, Tang X, Zhang ZF, Velikina R, Shi S and Le AD: Nicotine induces hypoxia-inducible factor-1alpha expression in human lung cancer cells via nicotinic acetylcholine receptor-mediated signaling pathways. Clin Cancer Res 13: 4686-4694, 2007.
9. Ma X, Jia Y, Zu S, Li R, Jia Y, Zhao Y, Xiao D, Dang N and Wang Y: α5 nicotinic acetylcholine receptor mediates nicotineinduced HIF-1α and VEGF expression in non-small cell lung cancer. Toxicol Appl Pharmacol 278: 172-179, 2014.
10. Nurwidya F, Takahashi F, Murakami A and Takahashi K: Epithelial mesenchymal transition in drug resistance and metastasis of lung cancer. Cancer Res Treat 44: 151-156, 2012.
11. Wang L, Zhang X, Liu J, Shen L and Li Z: Tea consumption and lung cancer risk: A meta-analysis of case-control and cohort studies. Nutrition 30: 1122-1127, 2014.
12. Lin IH, Ho ML, Chen HY, Lee HS, Huang CC, Chu YH, Lin SY, Deng YR, He YH, Lien YH, et al: Smoking, green tea consumption, genetic polymorphisms in the insulin-like growth factors and lung cancer risk. PLoS One 7: e30951, 2012.
13. Ravindranath MH, Ramasamy V, Moon S, Ruiz C and Muthugounder S: Differential growth suppression of human melanoma cells by tea (Camellia sinensis) epicatechins (ECG, EGC and EGCG). Evid Based Complement Alternat Med 6: 523-530, 2009.
14. Du GJ, Zhang Z, Wen XD, Yu C, Calway T, Yuan CS and Wang CZ: Epigallocatechin gallate (EGCG) is the most effective cancer chemopreventive polyphenol in green tea. Nutrients 4: 1679-1691, 2012.
15. Wang F, Chang Z, Fan Q and Wang L: Epigallocatechin-3-gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase-2. Mol Med Rep 9: 1085-1089, 2014.
16. Zhang W, Yang P, Gao F, Yang J and Yao K: Effects of epigallocatechin gallate on the proliferation and apoptosis of the nasopharyngeal carcinoma cell line CNE2. Exp Ther Med 8: 1783-1788, 2014.
17. Li H, Li Z, Xu YM, Wu Y, Yu KK, Zhang C, Ji YH, Ding G and Chen FX: Epigallocatechin-3-gallate induces apoptosis, inhibits proliferation and decreases invasion of glioma cell. Neurosci Bull 30: 67-73, 2014.
18. Li X, Feng Y, Liu J, Feng X, Zhou K and Tang X: Epigallocatechin- 3-gallate inhibits IGF-I-stimulated lung cancer angiogenesis through downregulation of HIF-1α and VEGF expression. J Nutrigenet Nutrigenomics 6: 169-178, 2013.
19. Zhang Q, Tang X, Lu Q, Zhang Z, Rao J and Le AD: Green tea extract and (-)-epigallocatechin-3-gallate inhibit hypoxia- and serum-induced HIF-1alpha protein accumulation and VEGF expression in human cervical carcinoma and hepatoma cells. Mol Cancer Ther 5: 1227-1238, 2006.
20. He L, Zhang E, Shi J, Li X, Zhou K, Zhang Q, Le AD and Tang X: (-)-Epigallocatechin-3-gallate inhibits human papillomavirus (HPV)-16 oncoprotein-induced angiogenesis in non-small cell lung cancer cells by targeting HIF-1α. Cancer Chemother Pharmacol 71: 713-725, 2013.
21. Liu LC, Tsao TC, Hsu SR, Wang HC, Tsai TC, Kao JY and Way TD: EGCG inhibits transforming growth factor-β-mediated epithelial-to-mesenchymal transition via the inhibition of Smad2 and Erk1/2 signaling pathways in nonsmall cell lung cancer cells. J Agric Food Chem 60: 9863-9873, 2012.
22. Ko H, So Y, Jeon H, Jeong MH, Choi HK, Ryu SH, Lee SW, Yoon HG and Choi KC: TGF-β1-induced epithelial-mesenchymal transition and acetylation of Smad2 and Smad3 are negatively regulated by EGCG in human A549 lung cancer cells. Cancer Lett 335: 205-213, 2013.
23. Takahashi A, Watanabe T, Mondal A, Suzuki K, Kurusu-Kanno M, Li Z, Yamazaki T, Fujiki H and Suganuma M: Mechanism-based inhibition of cancer metastasis with (-)-epigallocatechin gallate. Biochem Biophys Res Commun 443: 1-6, 2014.
24. Nilsson I, Shibuya M and Wennström S: Differential activation of vascular genes by hypoxia in primary endothelial cells. Exp Cell Res 299: 476-485, 2004.
25. Li G, He L, Zhang E, Shi J, Zhang Q, Le AD, Zhou K and Tang X: Overexpression of human papillomavirus (HPV) type 16 oncoproteins promotes angiogenesis via enhancing HIF-1α and VEGF expression in non-small cell lung cancer cells. Cancer Lett 311: 160-170, 2011.
26. Skinner HD, Zheng JZ, Fang J, Agani F and Jiang BH: Vascular endothelial growth factor transcriptional activation is mediated by hypoxia-inducible factor 1alpha, HDM2, and p70S6K1 in response to phosphatidylinositol 3-kinase/AKT signaling. J Biol Chem 279: 45643-45651, 2004.
27. Wang L, Gu F, Ma N, Zhang L, Bian JM and Cao HY: CIP2A expression is associated with altered expression of epithelial-mesenchymal transition markers and predictive of poor prognosis in pancreatic ductal adenocarcinoma. Tumour Biol 34: 2309-2313, 2013.
28. Zhao D, Yang K, Tang XF, Lin NN and Liu JY: Expression of integrin-linked kinase in adenoid cystic carcinoma of salivary glands correlates with epithelial-mesenchymal transition markers and tumor progression. Med Oncol 30: 619, 2013.
29. Balanis N, Wendt MK, Schiemann BJ, Wang Z, Schiemann WP and Carlin CR: Epithelial to mesenchymal transition promotes breast cancer progression via a fibronectin-dependent STAT3 signaling pathway. J Biol Chem 288: 17954-17967, 2013.
30. Xing Y, Qi J, Deng S, Wang C, Zhang L and Chen J: Small interfering RNA targeting ILK inhibits metastasis in human tongue cancer cells through repression of epithelial-to-mesenchymal transition. Exp Cell Res 319: 2058-2072, 2013.
31. López-Novoa JM and Nieto MA: Inflammation and EMT: An alliance towards organ fibrosis and cancer progression. EMBO Mol Med 1: 303-314, 2009.
32. Pirozzi G, Tirino V, Camerlingo R, Franco R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N and Rocco G: Epithelial to mesenchymal transition by TGFβ-1 induction increases stemness characteristics in primary non small cell lung cancer cell line. PLoS One 6: e21548, 2011.
33. Kim H, Yoo SB, Sun P, Jin Y, Jheon S, Lee CT and Chung JH: Alteration of the E-cadherin/β-catenin complex is an independent poor prognostic factor in lung adenocarcinoma. Korean J Pathol 47: 44-51, 2013.
34. Zhan H, Liang H, Liu X, Deng J, Wang B and Hao X: Expression of Rac1, HIF-1α, and VEGF in gastric carcinoma: Correlation with angiogenesis and prognosis. Onkologie 36: 102-107, 2013.
35. Simonetti O, Lucarini G, Rubini C, Goteri G, Zizzi A, Staibano S, Campanati A, Ganzetti G, Di Primio R and Offidani A: Microvessel density and VEGF, HIF-1α expression in primary oral melanoma: Correlation with prognosis. Oral Dis 19: 620-627, 2013.
36. Kang FW, Gao Y, Que L, Sun J and Wang ZL: Hypoxia-inducible factor-1α overexpression indicates poor clinical outcomes in tongue squamous cell carcinoma. Exp Ther Med 5: 112-118, 2013.
37. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, Liu J, Wang Q, Zhu J, Feng X, et al: Hypoxia induces epithelial-mesenchymal transition via activation of SNAI1 by hypoxia-inducible factor -1α in hepatocellular carcinoma. BMC Cancer 13: 108-117, 2013.
38. Ning Q, Liu C, Hou L, Meng M, Zhang X, Luo M, Shao S, Zuo X and Zhao X: Vascular endothelial growth factor receptor-1 activation promotes migration and invasion of breast cancer cells through epithelial-mesenchymal transition. PLoS One 8: e65217, 2013.
39. Semenza GL: Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634, 2010.
40. Jiang Y, Cukic B, Adjeroh DA, Skinner HD, Lin J, Shen QJ and Jiang BH: An algorithm for identifying novel targets of transcription factor families: Application to hypoxia-inducible factor 1 targets. Cancer Inform 7: 75-89, 2009.
41. Kaidi A, Qualtrough D, Williams AC and Paraskeva C: Direct transcriptional up-regulation of cyclooxygenase-2 by hypoxiainducible factor (HIF)-1 promotes colorectal tumor cell survival and enhances HIF-1 transcriptional activity during hypoxia. Cancer Res 66: 6683-6691, 2006.
42. Obacz J, Pastorekova S, Vojtesek B and Hrstka R: Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Mol Cancer 12: 93, 2013.
43. Zhang E, Feng X, Liu F, Zhang P, Liang J and Tang X: Roles of PI3K/Akt and c-Jun signaling pathways in human papillomavirus type 16 oncoprotein-induced HIF-1α, VEGF, and IL-8 expression and in vitro angiogenesis in non-small cell lung cancer cells. PLoS One 9: e103440, 2014.
44. Yu H, Zhang L and Liu P: CXCR7 signaling induced epithelial-mesenchymal transition by AKT and ERK pathways in epithelial ovarian carcinomas. Tumour Biol: Oct 31, 2014 (Epub ahead of print).
45. Wojtalla A and Arcaro A: Targeting phosphoinositide 3-kinase signalling in lung cancer. Crit Rev Oncol Hematol 80: 278-290, 2011.
46. Zhang J, Cao J, Ma S, et al: Tumor hypoxia enhances non-small cell lung cancer metastasis by selectively promoting macrophage M2 polarization through the activation of ERK signaling. Oncotarget Oct 5: 9664-9677, 2014.
47. Beck JT, Ismail A and Tolomeo C: Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: An emerging treatment strategy for squamous cell lung carcinoma. Cancer Treat Rev 40: 980-989, 2014.
48. Stinchcombe TE and Johnson GL: MEK inhibition in non-small cell lung cancer. Lung Cancer 86: 121-125, 2014.